Trial Profile
A Phase IIIb, Non-randomized, Open-label, Multi-Centre, Follow-on Safety Trial of Monthly Doses of Degarelix in Patients With Prostate Cancer. [Ensayo clínico fase IIIb, no aleatorizado, abierto, multicéntrico, de seguimiento de la seguridad de dosis mensuales de degarelix en pacientes con cáncer de próstata.]
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Oct 2021
Price :
$35
*
At a glance
- Drugs Degarelix (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Ferring Pharmaceuticals
- 17 Oct 2012 Planned number of patients changed from 345 to 700.
- 18 Apr 2012 Planned number of patients changed from 200 to 345 as reported by European Clinical Trials Database.
- 10 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.